OpenEvidence AI Tool Widely Adopted by U.S. Physicians
OpenEvidence, an AI-powered medical search engine, is now utilized by nearly two-thirds of U.S. physicians to assist in clinical decision-making and medical education.
Over the past two years, OpenEvidence, an AI-driven medical search tool, has been increasingly adopted by medical professionals across the United States. The platform assists physicians in making clinical decisions, refreshing medical knowledge, and preparing for licensing examinations. In April alone, OpenEvidence was utilized in approximately 27 million clinical encounters, according to company data.
Dr. Anupam Jena, an internal medicine physician at Massachusetts General Hospital and professor of healthcare policy at Harvard, noted the tool's rapid growth, stating, "Everyone is using it. Its growth really has been exponential." The company reports that nearly 65% of U.S. physicians, roughly 650,000 doctors, actively use OpenEvidence, with an additional 1.2 million users internationally.
OpenEvidence functions as an AI-powered medical search engine, analyzing extensive databases of healthcare research to provide suggestions on clinical decisions and medication options. It also offers features such as writing patient discharge notes and creating custom study tools for medical exams. The platform is accessible through its website or a mobile app, requiring practitioners to register with their unique healthcare ID number. Once registered, users can ask unlimited medical questions at no cost.
The company emphasizes that OpenEvidence is designed to supplement, not replace, physicians' judgment. Its terms of service state that the platform is "in no way intended to serve as a diagnostic service or platform, to provide certainty with respect to a diagnosis, to recommend a particular product or therapy or to otherwise substitute for the clinical judgment of a qualified healthcare professional."
Despite its widespread adoption, some experts express concerns about potential inaccuracies, incomplete answers, and the lack of rigorous scientific studies on the tool's impact on patient outcomes. Additionally, there is apprehension that increased reliance on OpenEvidence could affect doctors' critical thinking and evaluation skills.
OpenEvidence has secured partnerships and licensing agreements with prestigious medical journals, including The New England Journal of Medicine and the Journal of the American Medical Association, to ensure access to high-quality data. The company has also raised significant funding, with a recent $250 million Series D round co-led by Thrive Capital and DST Global, bringing its valuation to $12 billion.
As AI tools like OpenEvidence become more integrated into medical practice, ongoing evaluation of their effectiveness and impact on patient care remains essential.